Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 23, 2019

Ramucirumab After Sorafenib in Patients With Advanced HCC and Increased α-Fetoprotein Concentrations

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Ramucirumab After Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2019 Jan 18;[EPub Ahead of Print], AX Zhu, Y-K Kang, C-J Yen, et al

Further Reading